Evaluating the novel application of cyclosporine 0.1% in ocular surface disease

References

• Baudouin C, Aragona P, Messmer EM, et al. Role of hyperosmolarity in the pathogenesis and management of dry eye disease: proceedings of the OCEAN group meeting. Ocul Surf. 2013;11:246–258.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016;100:300–306.
   PubMed Web of Science ®Google Scholar
• The definition and classification of dry eye disease: report of the definition and classification subcommittee of the International dry eye workshop (2007). Ocul Surf. 2007;5:75–92.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nelson JD, Azar DT, et al. TFOS DEWS II report executive summary. Ocul Surf 2017;15:802–812.
   PubMed Web of Science ®Google Scholar
• Cho YK, Kim MS. Dry eye after cataract surgery and associated intraoperative risk factors. Korean J Ophthalmol. 2009;23:65–73.
   PubMedGoogle Scholar
• Liu X, Gu YS, Xu YS. Changes of tear film and tear secretion after phacoemulsification in diabetic patients. J Zhejiang Univ Sci B. 2008;9:324–328.
   PubMed Web of Science ®Google Scholar
• Ram J, Gupta A, Brar G, et al. Outcomes of phacoemulsification in patients with dry eye. J Cataract Refract Surg. 2002;28:1386–1389.
   PubMed Web of Science ®Google Scholar
• LASIK TI. and the ocular surface. Cornea. 2008;27(Suppl 1):S70–S76.
   PubMedGoogle Scholar
• Yu Y, Hua H, Wu M, et al. Evaluation of dry eye after femtosecond laser-assisted cataract surgery. J Cataract Refract Surg. 2015;41:2614–2623.
   PubMed Web of Science ®Google Scholar
• Jabbur NS, Sakatani K, O’Brien TP. Survey of complications and recommendations for management in dissatisfied patients seeking a consultation after refractive surgery. J Cataract Refract Surg. 2004;30:1867–1874.
   PubMed Web of Science ®Google Scholar
• Bourne RR, Taylor HR, Flaxman SR, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990-2010: a meta-analysis. PLoS One. 2016;11:e0162229.
   PubMed Web of Science ®Google Scholar
• Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–267.
   PubMed Web of Science ®Google Scholar
• Fogagnolo P, Rossetti L. Medical treatment of glaucoma: present and future. Expert Opin Investig Drugs. 2011;20:947–959.
   PubMed Web of Science ®Google Scholar
• Konstas AGP, Quaranta L, Katsanos A. Fixed combination therapies in glaucoma. In: Shaarawy TM, Sherwood MB, Hitchings RA, et al., editors. Glaucoma. 2nd ed. New York: Elsevier Saunders; 2015. p. 583–592.
   Google Scholar
• Society EG. Terminology and guidelines for glaucoma. 4th ed. Savona, Italy: PubliComm; 2014.
   Google Scholar
• Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29:312–334.
   PubMed Web of Science ®Google Scholar
• Boimer C, Birt CM. Preservative exposure and surgical outcomes in glaucoma patients: the PESO study. J Glaucoma. 2013;22:730–735.
   PubMed Web of Science ®Google Scholar
• Fechtner RD, Godfrey DG, Budenz D, et al. Prevalence of ocular surface complaints in patients with glaucoma using topical intraocular pressure-lowering medications. Cornea. 2010;29:618–621.
   PubMed Web of Science ®Google Scholar
• Freeman PD, Kahook MY. Preservatives in topical ophthalmic medications: historical and clinical perspectives. Expert Rev Ophthalmol. 2014;4:59–64.
   Google Scholar
• Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17:341–349.
   PubMed Web of Science ®Google Scholar
• Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. J Glaucoma. 2008;17:350–355.
   PubMed Web of Science ®Google Scholar
• Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264–1268.
   PubMed Web of Science ®Google Scholar
• Skalicky SE, Goldberg I, McCluskey P. Ocular surface disease and quality of life in patients with glaucoma. Am J Ophthalmol. 2012;153:1–9 e2.
   PubMed Web of Science ®Google Scholar
• Wilson LA. To preserve or not to preserve, is that the question? Br J Ophthalmol. 1996;80:583–584.
   PubMed Web of Science ®Google Scholar
• Yalvac IS, Gedikoglu G, Karagoz Y, et al. Effects of antiglaucoma drugs on ocular surface. Acta Ophthalmol Scand. 1995;73:246–248.
   PubMedGoogle Scholar
• Konstas AG, Hollo G. Preservative-free tafluprost/timolol fixed combination: a new opportunity in the treatment of glaucoma. Expert Opin Pharmacother. 2016;17:1271–1283.
   PubMed Web of Science ®Google Scholar
• Hollo G, Katsanos A, Boboridis KG, et al. Preservative-free prostaglandin analogs and prostaglandin/timolol fixed combinations in the treatment of glaucoma: efficacy, safety and potential advantages. Drugs. 2018;78:39–64.
   PubMed Web of Science ®Google Scholar
• Jones L, Downie LE, Korb D, et al. TFOS DEWS II management and therapy report. Ocul Surf. 2017;15:575–628.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Irkec M, Messmer EM, et al. Clinical impact of inflammation in dry eye disease: proceedings of the ODISSEY group meeting. Acta Ophthalmol. 2018;96:111–119.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Ikervis authorisation. 2017. [ cited 2017 Apr 30]; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002066/human_med_001851.jsp&mid=WC0b01ac058001d124
   Google Scholar
• Pflugfelder SC, Baudouin C. Challenges in the clinical measurement of ocular surface disease in glaucoma patients. Clin Ophthalmol. 2011;5:1575–1583.
   PubMedGoogle Scholar
• Johnson ME, Murphy PJ. Changes in the tear film and ocular surface from dry eye syndrome. Prog Retin Eye Res. 2004;23:449–474.
   PubMed Web of Science ®Google Scholar
• Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II definition and classification report. Ocul Surf. 2017;15:276–283.
   PubMed Web of Science ®Google Scholar
• Tseng SC. A practical treatment algorithm for managing ocular surface and tear disorders. Cornea. 2011;30(Suppl 1):S8–S14.
   PubMedGoogle Scholar
• Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet. 1978;2:1323–1327.
   PubMed Web of Science ®Google Scholar
• Williams DL. A comparative approach to topical cyclosporine therapy. Eye (Lond). 1997;11(Pt 4):453–464.
   PubMed Web of Science ®Google Scholar
• Fruman DA, Klee CB, Bierer BE, et al. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci U S A. 1992;89:3686–3690.
   PubMed Web of Science ®Google Scholar
• Klee CB, Ren H, Wang X. Regulation of the calmodulin-stimulated protein phosphatase, calcineurin. J Biol Chem. 1998;273:13367–13370.
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez S, Redondo JM. Inhibitors of the calcineurin/NFAT pathway. Curr Med Chem. 2004;11:997–1007.
   PubMed Web of Science ®Google Scholar
• Halloran PF, Kung L, Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplant Proc. 1998;30:2167–2170.
   PubMed Web of Science ®Google Scholar
• Winslow MM, Neilson JR, Crabtree GR. Calcium signalling in lymphocytes. Curr Opin Immunol. 2003;15:299–307.
   PubMed Web of Science ®Google Scholar
• Horsley V, Pavlath GK. NFAT: ubiquitous regulator of cell differentiation and adaptation. J Cell Biol. 2002;156:771–774.
   PubMed Web of Science ®Google Scholar
• Waldmeier PC, Zimmermann K, Qian T, et al. Cyclophilin D as a drug target. Curr Med Chem. 2003;10:1485–1506.
   PubMed Web of Science ®Google Scholar
• Li Y, Johnson N, Capano M, et al. Cyclophilin-D promotes the mitochondrial permeability transition but has opposite effects on apoptosis and necrosis. Biochem J. 2004;383:101–109.
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004;305:626–629.
   PubMed Web of Science ®Google Scholar
• Coster DJ, Shepherd WF, Fook TC, et al. Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet. 1979;2:688–689.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Wiederholt M. [Local treatment of corneal transplants in the human with cyclosporin A]. Klin Monbl Augenheilkd. 1985;187:92–96.
   PubMed Web of Science ®Google Scholar
• Holland EJ, Olsen TW, Ketcham JM, et al. Topical cyclosporin A in the treatment of anterior segment inflammatory disease. Cornea. 1993;12:413–419.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Restasis drug approval package. [ cited 2017 Apr 30]; Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/21-023_Restasis.cfm
   Google Scholar
• Kymionis GD, Bouzoukis DI, Diakonis VF, et al. Treatment of chronic dry eye: focus on cyclosporine. Clin Ophthalmol. 2008;2:829–836.
   PubMedGoogle Scholar
• Tatlipinar S, Akpek EK. Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol. 2005;89:1363–1367.
   PubMed Web of Science ®Google Scholar
• Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA phase 3 study group. Ophthalmology. 2000;107:631–639.
   PubMed Web of Science ®Google Scholar
• Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The cyclosporin A phase 2 study group. Ophthalmology. 2000;107:967–974.
   PubMed Web of Science ®Google Scholar
• Barber LD, Pflugfelder SC, Tauber J, et al. Phase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 years. Ophthalmology. 2005;112:1790–1794.
   PubMed Web of Science ®Google Scholar
• Sall KN, Cohen SM, Christensen MT, et al. An evaluation of the efficacy of a cyclosporine-based dry eye therapy when used with marketed artificial tears as supportive therapy in dry eye. Eye Contact Lens. 2006;32:21–26.
   PubMedGoogle Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trial. Eur J Ophthalmol. 2016;26:287–296.
   PubMed Web of Science ®Google Scholar
• Hoy SM. Ciclosporin ophthalmic emulsion 0.1%: a review in severe dry eye disease. Drugs2017771909–1916
   PubMed Web of Science ®Google Scholar
• Stern ME, Gao J, Schwalb TA, et al. Conjunctival T-cell subpopulations in Sjogren’s and non-Sjogren’s patients with dry eye. Invest Ophthalmol Vis Sci. 2002;43:2609–2614.
   PubMed Web of Science ®Google Scholar
• Stern ME, Gao J, Siemasko KF, et al. The role of the lacrimal functional unit in the pathophysiology of dry eye. Exp Eye Res. 2004;78:409–416.
   PubMed Web of Science ®Google Scholar
• Kung L, Batiuk TD, Palomo-Pinon S, et al. Tissue distribution of calcineurin and its sensitivity to inhibition by cyclosporine. Am J Transplant. 2001;1:325–333.
   PubMed Web of Science ®Google Scholar
• Strong B, Farley W, Stern ME, et al. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca. Cornea. 2005;24:80–85.
   PubMed Web of Science ®Google Scholar
• Abu el-Asrar AM, Van Den Oord JJ, Geboes K, et al. Immunopathological study of vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 1989;227:374–379.
   PubMed Web of Science ®Google Scholar
• el-Asrar AM, Tabbara KF, Geboes K, et al. An immunohistochemical study of topical cyclosporine in vernal keratoconjunctivitis. Am J Ophthalmol. 1996;121:156–161.
   PubMed Web of Science ®Google Scholar
• Bleik JH, Tabbara KF. Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology. 1991;98:1679–1684.
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther. 2009;25:365–372.
   PubMed Web of Science ®Google Scholar
• Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology. 1991;98:150–158.
   PubMed Web of Science ®Google Scholar
• Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratoconjunctivitis. Ophthalmology. 1991;98:1190–1196.
   PubMed Web of Science ®Google Scholar
• Akpek EK, Dart JK, Watson S, et al. A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology. 2004;111:476–482.
   PubMed Web of Science ®Google Scholar
• Hingorani M, Moodaley L, Calder VL, et al. A randomized, placebo-controlled trial of topical cyclosporin A in steroid-dependent atopic keratoconjunctivitis. Ophthalmology. 1998;105:1715–1720.
   PubMed Web of Science ®Google Scholar
• Pfister RR, Murphy GE. Corneal ulceration and perforation associated with Sjogren’s syndrome. Arch Ophthalmol. 1980;98:89–94.
   PubMedGoogle Scholar
• Kervick GN, Pflugfelder SC, Haimovici R, et al. Paracentral rheumatoid corneal ulceration. Clinical features and cyclosporine therapy. Ophthalmology. 1992;99:80–88.
   PubMed Web of Science ®Google Scholar
• Liegner JT, Yee RW, Wild JH. Topical cyclosporine therapy for ulcerative keratitis associated with rheumatoid arthritis. Am J Ophthalmol. 1990;109:610–612.
   PubMed Web of Science ®Google Scholar
• Nagra PK, Rapuano CJ, Cohen EJ, et al. Thygeson’s superficial punctate keratitis: ten years’ experience. Ophthalmology. 2004;111:34–37.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC, Karpecki PM, Perez VL. Treatment of blepharitis: recent clinical trials. Ocul Surf. 2014;12:273–284.
   PubMed Web of Science ®Google Scholar
• Reinhard T, Sundmacher R. Topical cyclosporin A in Thygeson’s superficial punctate keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237:109–112.
   PubMed Web of Science ®Google Scholar
• Perry HD, Doshi-Carnevale S, Donnenfeld ED, et al. Efficacy of commercially available topical cyclosporine A 0.05% in the treatment of meibomian gland dysfunction. Cornea. 2006;25:171–175.
   PubMed Web of Science ®Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea. 1998;17:584–589.
   PubMed Web of Science ®Google Scholar
• Stern ME, Beuerman RW, Fox RI, et al. A unified theory of the role of the ocular surface in dry eye. Adv Exp Med Biol. 1998;438:643–651.
   PubMed Web of Science ®Google Scholar
• Geerling G, Baudouin C, Aragona P, et al. Emerging strategies for the diagnosis and treatment of meibomian gland dysfunction: proceedings of the OCEAN group meeting. Ocul Surf. 2017;15:179–192.
   PubMed Web of Science ®Google Scholar
• Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. Ophthalmology. 1999;106:811–816.
   PubMed Web of Science ®Google Scholar
• Laibovitz RA, Solch S, Andriano K, et al. Pilot trial of cyclosporine 1% ophthalmic ointment in the treatment of keratoconjunctivitis sicca. Cornea. 1993;12:315–323.
   PubMed Web of Science ®Google Scholar
• Power WJ, Mullaney P, Farrell M, et al. Effect of topical cyclosporin A on conjunctival T cells in patients with secondary Sjogren’s syndrome. Cornea. 1993;12:507–511.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Gipson IK. Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol. 2002;120:330–337.
   PubMed Web of Science ®Google Scholar
• Kunert KS, Tisdale AS, Stern ME, et al. Analysis of topical cyclosporine treatment of patients with dry eye syndrome: effect on conjunctival lymphocytes. Arch Ophthalmol. 2000;118:1489–1496.
   PubMed Web of Science ®Google Scholar
• Turner K, Pflugfelder SC, Ji Z, et al. Interleukin-6 levels in the conjunctival epithelium of patients with dry eye disease treated with cyclosporine ophthalmic emulsion. Cornea. 2000;19:492–496.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Schmitt M, Bourges JL, et al. Cyclosporine A delivery to the eye: a comprehensive review of academic and industrial efforts. Eur J Pharm Biopharm. 2017;117:14–28.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Philips B, et al. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits. Cornea. 2013;32:345–354.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Felt-Baeyens O, Besseghir K, et al. Cyclosporine A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56:307–318.
   PubMed Web of Science ®Google Scholar
• Daull P, Lallemand F, Garrigue JS. Benefits of cetalkonium chloride cationic oil-in-water nanoemulsions for topical ophthalmic drug delivery. J Pharm Pharmacol. 2014;66:531–541.
   PubMed Web of Science ®Google Scholar
• Ambroziak AM, Szaflik J, Szaflik JP, et al. Immunomodulation on the ocular surface: a review. Cent Eur J Immunol. 2016;41:195–208.
   PubMed Web of Science ®Google Scholar
• Oy S IKERVIS 1 mg/mL eye drops, emulsion: EU summary of product characteristics. 2017. [ cited 2018 Jan 28]; Available from: http://www.ema.europa.eu/ema/
   Google Scholar
• Baudouin C, de la Maza MS, Amrane M, et al. One-year efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease. Eur J Ophthalmol. 2017;27:678–685.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27:520–530.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Van Setten G, Amrane M, et al. Author’s reply to: “Concerns over: efficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease”. Eur J Ophthalmol. 2017;27:e194–e195.
   Google Scholar
• Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporine: pharmacology and clinical uses. Surv Ophthalmol. 2009;54:321–338.
   PubMed Web of Science ®Google Scholar
• Lallemand F, Daull P, Benita S, et al. Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb. J Drug Deliv. 2012;2012:604204.
   PubMedGoogle Scholar
• Amrane M, Creuzot-Garcher C, Robert PY, et al. Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease - a randomised comparative study. J Fr Ophtalmol. 2014;37:589–598.
   PubMed Web of Science ®Google Scholar
• Robert PY, Cochener B, Amrane M, et al. Efficacy and safety of a cationic emulsion in the treatment of moderate to severe dry eye disease: a randomized controlled study. Eur J Ophthalmol. 2016;26:546–555.
   PubMed Web of Science ®Google Scholar
• Daull P, Feraille L, Barabino S, et al. Efficacy of a new topical cationic emulsion of cyclosporine A on dry eye clinical signs in an experimental mouse model of dry eye. Exp Eye Res. 2016;153:159–164.
   PubMed Web of Science ®Google Scholar
• Di Pascuale MA, Goto E, Tseng SC. Sequential changes of lipid tear film after the instillation of a single drop of a new emulsion eye drop in dry eye patients. Ophthalmology. 2004;111:783–791.
   PubMed Web of Science ®Google Scholar
• Leonardi A, Messmer EM, Labetoulle M, et al. Efficacy and safety of 0.1% ciclosporin A cationic emulsion in dry eye disease: a pooled analysis of two double-masked, randomised, vehicle-controlled phase III clinical studies. Br J Ophthalmol. 2018.
   Google Scholar
• Administration USFD. FDA approves new medication for dry eye disease. 2016 [cited 2017 Oct]; Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm510720.htm
   Google Scholar
• Pflugfelder SC, Stern M, Zhang S, et al. LFA-1/ICAM-1 Interaction as a therapeutic target in dry eye disease. J Ocul Pharmacol Ther. 2017;33:5–12.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Figueiredo FC, Messmer EM, et al. A randomized study of the efficacy and safety of 0.1% cyclosporine A cationic emulsion in treatment of moderate to severe dry eye. Eur J Ophthalmol. 2017;27:520–530.
   PubMed Web of Science ®Google Scholar
• Pisella PJ, Labetoulle M, Doan S, et al. Topical ocular 0.1% cyclosporine A cationic emulsion in dry eye disease patients with severe keratitis: experience through the French early-access program. Clin Ophthalmol. 2018;12:289–299.
   PubMed Web of Science ®Google Scholar
• Moore QL, De Paiva CS, Pflugfelder SC. Effects of Dry Eye Therapies on Environmentally Induced Ocular Surface Disease. Am J Ophthalmol. 2015;160:135–42 e1.
   PubMed Web of Science ®Google Scholar
• Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137:337–342.
   PubMed Web of Science ®Google Scholar
• Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115:109–115.
   PubMed Web of Science ®Google Scholar
• Batra R, Tailor R, Mohamed S. Ocular surface disease exacerbated glaucoma: optimizing the ocular surface improves intraocular pressure control. J Glaucoma. 2014;23:56–60.
   PubMed Web of Science ®Google Scholar
• Foulks GN, Nichols KK, Bron AJ, et al. Improving awareness, identification, and management of meibomian gland dysfunction. Ophthalmology. 2012;119:S1–12.
   PubMed Web of Science ®Google Scholar
• Prabhasawat P, Tesavibul N, Mahawong W. A randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunction. Cornea. 2012;31:1386–1393.
   PubMed Web of Science ®Google Scholar
• Qiao J, Yan X. Emerging treatment options for meibomian gland dysfunction. Clin Ophthalmol. 2013;7:1797–1803.
   PubMedGoogle Scholar
• Thode AR, Latkany RA. Current and Emerging Therapeutic Strategies for the Treatment of Meibomian Gland Dysfunction (MGD). Drugs. 2015;75:1177–1185.
   PubMed Web of Science ®Google Scholar
• Saini M, Dhiman R, Dada T, et al. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications. Eye (Lond). 2015;29:808–814.
   PubMed Web of Science ®Google Scholar
• Cho HK, Park MH, Moon JI. The effect of additional topical cyclosporine or vitamin A on the ocular surface during antiglaucoma medication administration. Ophthalmic Res. 2012;48:139–145.
   PubMed Web of Science ®Google Scholar